419 related articles for article (PubMed ID: 24602464)
1. Anti-complement therapy for glomerular diseases.
Bomback AS
Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab in the treatment of membranoproliferative glomerulonephritis.
Bomback AS
Nephron Clin Pract; 2014; 128(3-4):270-6. PubMed ID: 25402185
[TBL] [Abstract][Full Text] [Related]
3. Treatment of C3 glomerulopathy with complement blockers.
Vivarelli M; Emma F
Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
Nester CM; Brophy PD
Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
[TBL] [Abstract][Full Text] [Related]
5. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
6. C3 glomerulopathy: A new complement-based entity.
de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
[TBL] [Abstract][Full Text] [Related]
7. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
8. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
Fakhouri F; Frémeaux-Bacchi V; Loirat C
Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
[TBL] [Abstract][Full Text] [Related]
9. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
10. Eculizumab in Pediatric Dense Deposit Disease.
Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
[TBL] [Abstract][Full Text] [Related]
11. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
Alfakeeh K; Azar M; Alfadhel M; Abdullah AM; Aloudah N; Alsaad KO
Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
[TBL] [Abstract][Full Text] [Related]
12. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab and refractory membranoproliferative glomerulonephritis.
Radhakrishnan S; Lunn A; Kirschfink M; Thorner P; Hebert D; Langlois V; Pluthero F; Licht C
N Engl J Med; 2012 Mar; 366(12):1165-6. PubMed ID: 22435384
[No Abstract] [Full Text] [Related]
14. Complement and glomerular disease: new insights.
Pickering M; Cook HT
Curr Opin Nephrol Hypertens; 2011 May; 20(3):271-7. PubMed ID: 21422921
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab for dense deposit disease and C3 glomerulonephritis.
Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
[TBL] [Abstract][Full Text] [Related]
16. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab for the treatment of dense-deposit disease.
Vivarelli M; Pasini A; Emma F
N Engl J Med; 2012 Mar; 366(12):1163-5. PubMed ID: 22435383
[No Abstract] [Full Text] [Related]
18. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
[No Abstract] [Full Text] [Related]
19. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
20. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options.
Sanghera P; Ghanta M; Ozay F; Ariyamuthu VK; Tanriover B
Am J Med Sci; 2017 Dec; 354(6):533-538. PubMed ID: 29208248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
